Read More

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The pharmaceutical industry has seen a surge in deal activities, with acquisitions totaling $27.8 billion since the year's start.

JANX

Read More

Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage

OCUP

Read More

Vertex Pharmaceutical’s Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.

ALPN